Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Cytoreductive Surgery

Research Leaders

8 sponsors active, led by KU Leuven

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed3
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07501494RecruitingPrimary

Evaluation of Quality Indicators in Patients Receiving Intensive Care and Their Influence on Outcome Indicators and Economic Indicators

NCT07567573Completed

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

NCT02030210Completed

CP4ACS - Delphi Study to Determine Appropriateness of STEMI Quality Indicators in Belgium

NCT01703689Not ApplicableCompletedPrimary

Impact of Educational and Professional Supportive Interventions on Nursing Home Quality Indicators

Showing all 4 trials

Research Network

Common Treatments

  • Cytoreductive Surgery1
  • Audit And Feedback1
  • Perioperative Management1
  • Systemic Chemotherapy1
  • Preoperative Evaluations1

Active Sponsors

  • KU Leuven1
  • ESGO Consortium of Accredited Centres1
  • Agence Régionale de la Santé - Midi Pyrénées1
  • European Pathway Association1
  • Charite University, Berlin, Germany1

Top Investigators

Related Conditions

  • Stemi1
  • Figo Stages Iii And Iv1
  • D0100511
  • Ovarian Cancer1
  • Advancedstage Ovarian Cancer1

Activity Timeline